

SCIENTIFIC REPORTS



OPEN

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients

Received: 28 September 2015

Accepted: 04 March 2016

Published: 18 March 2016

Yunfeng Ruan^{1,*}, Jie Jiang^{1,*}, Liang Guo², Yan Li³, Hailiang Huang^{4,5}, Lu Shen¹, Mengqi Luan¹, Mo Li¹, Huihui Du¹, Cheng Ma¹, Lin He¹, Xiaoqing Zhang⁶ & Shengying Qin^{1,7}

Epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) is an effective targeted therapy for advanced non-small cell lung cancer (NSCLC) but also causes adverse drug reactions (ADRs) e.g., skin rash and diarrhea. SNPs in the EGFR signal pathway, drug metabolism/ transport pathways and miRNA might contribute to the interpersonal difference in ADRs but biomarkers for therapeutic responses and ADRs to TKIs in Chinese population are yet to be fully investigated. We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. Rs884225 (T > C) in EGFR 3' UTR was significantly associated with lower risk of ADRs to erlotinib (p value = 0.0010, adjusted p value = 0.042). A multivariant interaction four-SNP model (rs884225 in EGFR 3'UTR, rs7787082 in ABCB1 intron, rs38845 in MET intron and rs3803300 in AKT1 5'UTR) was associated with ADRs in general and the more specific drug induced skin injury. The SNPs associated with both therapeutic responses and ADRs indicates they might share a common genetic basis. Our study provided potential biomarkers and clues for further research of biomarkers for therapeutic responses and ADRs in Chinese NSCLC patients.

Non-Small Cell Lung Cancers (NSCLC) make up the major part of lung cancers and are more resistant to chemotherapy and radiation therapy than small cell lung cancers¹. Previous research has proved that the hyperactivation of epidermal growth factor receptor (EGFR) pathway is the keystone in NSCLC oncogenesis^{2,3}. EGFR, located on the cell surface, activates proliferative and cell-survival signals by triggering the downstream kinase (such as AKT1)⁴. Based on the above molecular mechanism, targeted drug EGFR tyrosine kinase inhibitors (TKIs) (e.g. erlotinib, gefitinib and icotinib hydrochloride) were developed to treat patients with activating mutations in EGFR⁵. Clinical trials show that patients with activating mutations in EGFR responded better when treated with TKI than with chemotherapy⁶.

TKIs have a distinguishing adverse drug reaction (ADR) profile from chemotherapy and radiation therapy. They significantly lower the risk of typical severe ADRs to chemotherapy (e.g., neutropenia, thrombocytopenia, anaemia, nausea, constipation, increased ALT, fatigue). However, TKIs increase the risk of skin injury (mainly skin rash) and digestive tract injury (mainly diarrhea)^{7,8}, both of which still cause considerable discomfort.

¹Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China. ²The Fourth Hospital of Jinan City, Taishan Medical College, Jinan, China. ³Centre for Genomic Sciences, the University of Hong Kong, Hong Kong, SAR, China. ⁴Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, U.S.A. ⁵Broad Institute of Harvard and MIT, Cambridge, MA 02142, U.S.A. ⁶Department of Pharmacy, Shanghai pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. ⁷Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. ^{*}These authors contributed equally to this work. Correspondence and requests for materials should be addressed to X.Z. (email: zxqkitten@163.com) or S.Q. (email: chinsir@sjtu.edu.cn)

Identifying genetic biomarkers for drug response can facilitate personalized medication, which aims to maximize the therapeutic effect and minimize ADRs according to each individual's profile, e.g., genetic information. So far, studies have mainly focused on the activating mutations in the tyrosine kinase domain of EGFR and have proved that they are predictive biomarkers of therapeutic response to TKIs^{9–11}. However the proper biomarkers for TKIs induced ADRs have not yet been fully investigated.

Previous studies have revealed the mechanism of skin rash and diarrhea and their possible correlations with therapeutic responses. The potential for skin rash to be used as a predictor of therapeutic response to TKIs^{6,12,13} lies in the fact that skin injuries are “on-target” effects caused by the down-stream inhibition of EGFR signaling that interferes the proper function of epidermal cells^{14–16}. Unlike skin rash which is the specific response to the inhibition of EGFR signaling, TKI-induced diarrhea is the general result from interference caused by TKI drug molecules⁷.

Evidence has shown that SNPs in the EGFR signal pathway, drug metabolism/ transport pathways and miRNA SNPs might contribute to the interpersonal difference of therapeutic responses and ADRs to TKIs. A gene polymorphism that could influence the EGFR tyrosine kinase signaling might also affect the response to TKIs. Besides the coding SNPs in EGFR, the mutations in the regulation sequences of EGFR (promoter¹⁷, intron¹⁸, 5' UTR¹⁹) also play a role in carcinogenesis by influencing the expression of EGFR. Moreover, the variations in EGFR 5'UTR have been shown to be associated with skin rash (–216G/T)¹⁹ and diarrhea (–216 G/T and –191 C/A)²⁰ in NSCLC patients.

In addition to the polymorphism of the EGFR gene, mutations in other genes have also been found to influence the EGFR pathway. The activation of hepatocyte growth factor receptor MET mediates resistance to EGFR TKIs²¹. As important regulators of gene expression, miRNAs greatly influence the process of carcinogenesis²². Therefore we decided to include miRNA SNPs in our study.

In terms of pharmacokinetics, metabolism (mainly by CYP and UGT family) and transport (mainly by ABC family) of TKIs influenced both therapeutic responses and ADRs. After absorption and distribution, erlotinib and gefitinib are both transported by ATP-binding cassette family protein ABCB1 and ABCG2 and then metabolized in liver by CYP450 family. Erlotinib is metabolized primarily by CYP3A4 and CYP1A1 and marginally by CYP3A5, gefitinib primarily by CYP3A4 and marginally by CYP3A5 and CYP2D6. UGT1A1 is inhibited by erlotinib, CYP2C19 by gefitinib²³. CYP2C19 has also been reported to be associated with the pharmacokinetics of icotinib hydrochloride²⁴.

Studies have found the association between drug metabolism/transport genes and ADRs to TKIs. The polymorphisms of ABCG2 were found to be associated with gefitinib induced diarrhea^{25,26}. CYP2D6 genotype of reduced activity were associated with gefitinib-induced skin rash²⁷. However, a study conducted with 31 Japanese samples found that diarrhea were associated with exposure to gefitinib in plasma but not with common variations in metabolism and transport genes²⁸.

So far the pharmacogenetics association studies of TKIs have mainly focused on the single aspect of either therapeutic response or ADRs, and have been conducted mainly among Caucasian populations. In order to facilitate personalized medication among the Chinese population, we conducted biomarker study of therapeutic response and ADRs in 226 Chinese advance NSCLC patients. Based on the previous findings, we selected SNPs from EGFR signal pathway, drug metabolism/ transport pathway and miRNA SNPs for analysis.

Results

Patient Characteristics. The general characteristics of the patients are shown in Table 1. The patients who took different TKIs had similar age, progression free survival (PFS), occurrence rate of adverse reaction, objective responses. However, the gender ratio varied in the 3 groups. The patients who had objective response to icotinib hydrochloride showed lower occurrence rate of skin injury but the association between skin rash and therapeutic response still existed among these patients (Table 2).

We found that the therapeutic responses and ADRs were correlated among the patients as shown in Table 2. As expected, PFS and objective response, which are both indicators of therapeutic response, were highly correlated: among the patients who responded, their PFSs were similar no matter which drug they took. The same went with patients who did not respond. Patients who objectively responded to TKIs had approximately 1 year PFS, while PFS of those who did not was approximately 3 months. ADRs, especially skin injury were correlated with therapeutic reactions. However, digestive tract injury was less correlated. This tendency was more obvious among patients who took icotinib hydrochloride.

SNPs Associated with drug response and adverse drug reactions. As shown in Fig. 1, we found 9 SNPs from EGFR pathway and drug metabolism genes associated with objective response, 13 SNPs mainly from drug metabolism and transport genes associated with ADRs. 4 SNPs located in EGFR, CYP2C9, CYP2C19 and miRNA MIR141 were shared by the objective response group and ADR group. However, most associations found in this study did not survive multiple testing correction.

EGFR 3'UTR rs884225 was most significantly associated with both objective response to drug and ADR of all the SNPs analyzed in this study (Table 3). The association of its T > C allele with lower risk of ADR induced by erlotinib survived Bonferroni correction and FDR correction (unadjusted *p* value = 0.0010; adjusted *p* value = 0.042).

For the shared 4 SNPs, the alleles associated with more sensitive objective response were also associated with higher risk of ADR except CYP2C9 rs17885098 (T > C). Rs17885098 T allele was associated with objective response to gefitinib (unadjusted *p* value = 0.049193) while C allele was association with objective response to erlotinib (unadjusted *p* value = 0.0071) and skin injury induced by erlotinib (unadjusted *p* value = 0.0189).

For the 13 SNPs associated with ADRs, only 3 SNPs were associated with digestive tract injury (CYP1A2 SNPs rs2069521 G > A, rs4646425 C > T and miRNA SNP rs111718468).

Characteristics	All patients		erlotinib		gefitinib		icotinib hydrachloride		
	objective response	non response	objective response	non response	objective response	non response	objective response	non response	
No.	60	166	32	102	20	43	10	27	
Gender (male%)	51.67	65.66	56.25	73.53	40.00	39.53	60.00	81.48	
Smoke History no.	non	39	106	18	60	16	33	6	17
	former	7	13	5	11	1	4	1	1
	current	14	47	5	31	3	6	3	9
Family history No.	3	8	1	6	1	1	1	1	
Age (years)	range	37–83	29–83	44–80	39–83	37–83	29–77	39–78	33–80
	average	60.65	59.26	60.75	59.83	61.35	57.65	58.40	58.89
	SD	9.86	10.79	9.06	10.12	10.81	11.70	10.31	11.89
cancer stage	IIIa	10	25	7	14	3	8	0	5
	IIIb	7	13	5	10	1	1	1	2
	IV	43	128	20	78	16	34	9	20
PFS (months)	range	5–37	0.3–7.5	7–29	0.3–6.8	5–37	0.2–6.3	7–15	1–6
	average	11.95	3.29	11.98	3.03	13.05	3.33	9.12	3.25
	SD	6.52	1.93	5.69	1.95	8.47	2.02	2.55	1.78
Adverse Drug Reaction No.	total	36	25	20	11	15	8	3	5
	Skin	36	18	20	10	15	7	3	1
	digestive tract	18	12	10	3	7	2	2	4
	other toxic	1	2	1	1	0	0	0	1

Table 1. The characteristics of the patients. SD: standard deviation; No. : the number of.

Drug		PFS	objective reaction	skin injury
erlotinib	PFS	—	0.766**	—
	ADR	0.559**	0.540**	—
	skin injury	0.559**	0.540**	—
	digestive tract injury	0.533**	0.438**	0.584**
gefitinib	PFS	—	0.676**	—
	ADR	0.390**	0.545**	—
	skin injury	0.415**	0.573**	—
	digestive tract injury	0.223	0.404**	0.462**
icotinib hydrachloride	PFS	—	0.801**	—
	ADR	0.120	0.172	—
	skin injury	0.325*	0.376*	—
	digestive tract injury	0.110	0.062	0.555**

Table 2. The correlation of therapeutic responses and ADRs among patients. *p < 0.05, **p < 0.01.




Figure 1. The SNPs associated with therapeutic responses and ADRs.

Classification	Gene	SNP	P value	phenotype	Genotype number(frequency)			HWE p value	
objective response to drug	EGFR	rs884225	0.0226		T T	T C	C C		
				positive	20(0.333)	31(0.517)	9(0.150)	0.5916	
				negative	29(0.175)	94(0.566)	43(0.259)	0.0700	
	ABCG2	rs2231142	0.0828		A A	A C	C C		
				positive	8(0.138)	32(0.552)	18(0.310)	0.2959	
				negative	11(0.067)	79(0.482)	74(0.451)	0.0955	
objective response to erlotinib	CYP2C9	rs17885098	0.0191		C C	C T	T T		
				positive	2(0.062)	5(0.156)	25(0.781)	0.0456	
				negative	0(0.000)	9(0.088)	93(0.912)	0.6411	
	CYP2C19	rs4986893	0.0332		A A	A G	G G		
				positive	1(0.031)	5(0.156)	26(0.812)	0.2628	
				negative	0(0.000)	5(0.052)	91(0.948)	0.7934	
	AKT1	rs1130233	0.0433		A A	A G	G G		
				positive	2(0.100)	15(0.750)	3(0.150)	0.0243	
				negative	14(0.326)	18(0.419)	11(0.256)	0.2981	
	miRNA	rs111718468	0.0373		C C	C T	C T		
				positive	—	2(0.100)	18(0.900)	0.8139	
				negative	—	0(0.000)	42(1.000)	1.0000	
ADR to TKIs	EGFR	rs884225	0.0018		T T	T C	C C		
				positive	23(0.377)	27(0.443)	11(0.180)	0.5367	
				negative	26(0.158)	98(0.594)	41(0.248)	0.0111	
	ABCB1	rs1045642	0.0462		C C	C T	T T		
				positive	28(0.459)	25(0.410)	8(0.131)	0.5239	
				negative	47(0.285)	92(0.558)	26(0.158)	0.0864	
	ABCB1	rs10248420	0.0434		A A	A G	G G		
				positive	16(0.271)	30(0.508)	13(0.220)	0.8804	
				negative	62(0.403)	76(0.494)	16(0.104)	0.2990	
	ADR to erlotinib	ABCB1	rs1128503	0.0344		C C	C T	T T	
					positive	4(0.129)	20(0.645)	7(0.226)	0.0922
					negative	12(0.115)	42(0.404)	50(0.481)	0.4889
EGFR		rs884225	0.0010		T T	T C	C C		
				positive	15(0.484)	10(0.323)	6(0.194)	0.1000	
				negative	17(0.163)	60(0.577)	27(0.260)	0.0933	
ABCB1		rs7787082	0.0356		A A	A G	G G		
				positive	10(0.323)	11(0.355)	10(0.323)	0.1061	
				negative	13(0.125)	51(0.490)	40(0.385)	0.5984	
CYP1A2		rs762551	0.0126		A A	A C	C C		
				positive	7(0.233)	20(0.667)	3(0.100)	0.0503	
				negative	50(0.510)	36(0.367)	12(0.122)	0.1805	
ABCB1		rs10248420	0.0474		A A	A G	G G		
				positive	8(0.267)	14(0.467)	8(0.267)	0.7150	
				negative	37(0.385)	50(0.521)	9(0.094)	0.1748	
ADR to gefitinib		CYP1A1	rs1048943	0.1076		C C	C T	T T	
					positive	3(0.130)	10(0.435)	10(0.435)	0.8416
					negative	1(0.026)	12(0.308)	26(0.667)	0.7804
skin injury induced by TKIs	EGFR	rs884225	0.0073		T T	T C	C C		
				positive	20(0.370)	24(0.444)	10(0.185)	0.5589	
				negative	29(0.169)	101(0.587)	42(0.244)	0.0175	
	EGFR	rs884225	0.0033		T T	T C	C C		
				positive	14(0.467)	10(0.333)	6(0.200)	0.1221	
				negative	18(0.171)	60(0.571)	27(0.257)	0.1211	
	CYP2C9	rs17885098	0.0222		C C	C T	T T		
				positive	2(0.067)	4(0.133)	24(0.800)	0.0205	
				negative	0(0.000)	10(0.095)	95(0.905)	0.6084	
Continued									

Classification	Gene	SNP	P value	phenotype	Genotype number(frequency)			HWE p value
skin injury induced by erlotinib	ABCB1	rs1128503	0.0305	positive	3(0.100)	20(0.667)	7(0.233)	0.0503
				negative	13(0.124)	42(0.400)	50(0.476)	0.3750
					A A	A C	C C	
	CYP1A2	rs762551	0.0058	positive	6(0.207)	20(0.690)	3(0.103)	0.0338
				negative	51(0.515)	36(0.364)	12(0.121)	0.1663
					A A	A G	G G	
	CYP2C19	rs4986893	0.0113	positive	1(0.036)	5(0.179)	22(0.786)	0.3311
				negative	0(0.000)	5(0.050)	96(0.950)	0.7987
					A A	A G	G G	
digestive tract injury induced by TKIs	CYP1A2	rs2069521	0.0366	positive	1(0.033)	3(0.100)	26(0.867)	0.0585
				negative	0(0.000)	24(0.123)	171(0.877)	0.3599
					C C	C T	T T	
	CYP1A2	rs4646425	0.0361	positive	26(0.867)	3(0.100)	1(0.033)	0.0585
				negative	172(0.878)	24(0.122)	0(0.000)	0.3613
					C C	C T	C T	
	miRNA	rs111718468	0.0407	positive	—	3(0.100)	27(0.900)	0.7731
				negative	—	5(0.026)	190(0.974)	0.8561

Table 3. SNP sites associated with therapeutic responses and ADRs.

Phenotype	Haplotype	Case freq. %	Control freq. %	Fisher's p value	adjusted p value	Odds Ratio [95%CI]
ADRs to TKIs	ABCB1: C A G	41.4	31.5	0.046992	0.23496	1.562 [1.004~2.429]
	ABCB1: T G A	31.4	42.4	0.041685	0.208425	0.626 [0.398~0.984]
Skin injury induced by TKIs	CYP3A5, CYP3A4: C A A C T	4.6	1.2	0.034768	0.17384	3.816 [1.009~14.436]
	AKT: C G	23.8	15.2	0.03813	0.11439	1.755 [1.027~2.999]
ADRs to erlotinib	CYP3A5, CYP3A4: C G T C C	4.8	0.8	0.033093	0.198558	6.511 [0.911~46.559]
Skin injury induced by erlotinib	CYP3A5, CYP3A4: C G T C C	5.0	0.8	0.027835	0.16701	6.835 [0.955~48.917]

Table 4. Haplotypes associated with ADRs.

Haplotype Associated with adverse drug reactions. After analyzing all the genotyped genes, 3 blocks were identified in ABCB1 (contain rs1045642, rs7787082, rs10248420, 26kb) CYP3A5-CYP3A4 (contain rs15524, rs776746, rs12333983, rs4646440, rs2242480, 115kb) and AKT1 (contain rs2494732, rs1130233, 18kb) respectively. Rs1045642 and rs7787082 in ABCB1 had a strong linkage with $D' = 96$, $r^2 = 41$; rs15524 and rs776746 in CYP3A5 have a linkage with $D' = 96$, $r^2 = 88$; rs2494732 and rs1130233 in AKT1 have a linkage with $D' = 94$, $r^2 = 42$.

As shown in Table 4, only weak association existed between the haplotypes and ADRs. None of the associations was significant after adjustment.

Multivariate interaction analysis of objective response and adverse drug reaction. We investigated the probable multivariate interactions associated with PFS, objective response, ADRs with multifactor dimensionality reduction (MDR). Of all the possible multivariate models consisting of 2–4 genes, a four-gene model (rs884225 in EGFR 3'UTR, rs7787082 in ABCB1 intron, rs38845 in MET intron and rs3803300 in AKT1 5'UTR) was found to be significantly associated with ADRs as a whole as well as more specific skin injury alone in all the patients undergoing this study (Table 5). None of the 2- and 3-gene models were statistically significant.

Discussion

TKIs are an effective targeted therapy for advanced NSCLC patients with activating mutations in EGFR but can also cause ADRs, such as skin rash and diarrhea. According to previous findings, the adverse drug reactions (ADRs) of TKIs might be correlated with therapeutic response because of their shared mechanisms. We conducted this study to 1) further identify genetic biomarkers for predicting therapeutic responses and ADRs and 2) analyze the correlation between the therapeutic and adverse responses in Chinese Han population.

In terms of single SNPs analysis, we first identified a strong association between an SNP rs884225 C > T in 3'UTR of EGFR and increased risk of ADR to erlotinib. This association survived Bonferroni correction. SNP rs884225 C > T is very promising potential biomarkers for predicting ADRs to TKIs.

Various studies have shown that activating mutations in the EGFR pathway are associated with improved PFS and improved object response rate. The SNPs in the EGFR promoter and intron were also associated with ADRs to TKIs^{19,20}, but to our knowledge no association between polymorphism in EGFR 3' UTR and ADRs to TKIs has previously been found.

	P value	CVC	Bal. Acc. CV Training	Bal. Acc. CV Testing	Bal. Acc. Model Training	Bal. Acc. Model Testing	Bal. Acc. Overall
skin	0.021	9/10	0.8522	0.6343	0.852	0.6586	0.8472
ADR	0.032	9/10	0.835	0.6257	0.8349	0.6676	0.8296

Table 5. Multivariate interaction of ADRs and skin injury to TKIs. CVC: cross-validation consistency.

A previous study may reveal the mechanism underlying the association between rs884225 and responses to TKIs. Chu *et al.* discovered that rs884225 was significantly associated with bladder cancer risk. According to their bioinformatics analysis, rs884225 polymorphism lay within a predicted binding site for hsa-miR-214, but further *in vitro* validation found that the rs884225(T > C) alone would increase the expression of EGFR, not necessarily by the modulation of hsa-miR-214²⁹. We predict that 1) SNP rs884225 might affect the response to erlotinib by influencing the expression of EGFR and 2) this influence might exist in normal tissue cells as well as cancer cells, which would lead to a significant association with ADR and much weaker associations with therapeutic response.

In terms of multiple phenotypes and multigenic analysis, we found that therapeutic responses and ADRs to TKIs are correlated, which accords with previous findings indicating that skin rash could be used as a predictor of therapeutic response to TKIs^{6,11,12}. Digestive tract injuries were less correlated with therapeutic responses.

Although many other SNP associations did not survive multiple testing correction, they could indicate weak associations between SNPs and the phenotypes, which could be further validated with larger sample. First, The SNPs that were associated with both therapeutic and adverse responses indicated that therapeutic and adverse responses might share common genetic basics. Secondly, we assumed that TKIs induced diarrhea might have a genetic basis different from that of skin rash and therapeutic responses. This assumption also accords with our current knowledge that TKIs induced diarrhea might result from general interference caused by TKI molecule⁷ and it is supported by the following evidence: the association between SNPs and digestive injury was weaker than the association between SNPs and skin injury or ADRs as a whole; TKIs induced diarrhea was less correlated with therapeutic responses than TKIs induced skin rash. In addition, previous studies in Caucasian populations found that ABCG2 were associated with diarrhea^{25,26} but this finding was not repeated in our study. This indicated that the genetics basic of TKIs induced diarrhea might vary with different populations. From all above, we assume it may be possible to develop other population-specific biomarkers or therapy to reduce the risk of digestive tract injury in the treatment of NSCLC driven by EGFR activating mutations.

We also analyzed multivariate interaction among the EGFR signaling pathways, drug metabolism/transport pathways and miRNA with MDR method. A four-genes model (rs884225 in EGFR 3'UTR, rs7787082 in ABCB1 intron, rs38845 in MET intron and rs3803300 in AKT1 5'UTR) was associated with TKIs induced ADRs and skin rash. The model contains 1 SNP in the drug transport pathway, 2 in the EGFR signaling pathway and 1 in a gene that influences the EGFR pathway. In support for the fidelity of this model, some of the SNPs in this model were associated with other drug responses and oncogenesis. The genotype of rs7787082 in ABCB1 was mildly associated with risk of ADRs to erlotinib in this study (unadjusted p value = 0.0356). Allele rs7787082 G was associated with non-response to clozapine in Korean schizophrenia patients³⁰. Rs3803300 was associated with risk of schizophrenia and therapeutic response^{31,32} and risk of oral squamous cell carcinoma³³ and survival of early stage NSCLC³⁴. This multivariate model indicated that ADRs to TKIs might result from gene interaction among multiple pathways.

In conclusion, we found a strong association between SNP rs884225 and ADR to erlotinib. The multivariate model also indicated that ADRs to TKIs might be regulated by multivariate interactions. These positive results are potential biomarkers for predicting ADRs to TKIs. Other predictions made from our study (e.g. the SNPs that were associated with both therapeutic and adverse responses indicated that therapeutic and adverse responses might share common genetic basis) could serve as guideline for further validation and more in-depth biomarker research. Our study helped to implement personalized medication for Chinese NSCLC patients in terms of both theory and application.

Subjects and Methods

Patient recruitment. We recruited 226 NSCLC patients who underwent EGFR TKIs erlotinib, gefitinib and icotinib hydrochloride therapy through our clinical network in Shanghai. We collected their blood sample and clinical records including their gender, age at presentation, cancer family, history, smoking record, cancer diagnosis, pathologic type, stage, medication administration record of adverse reaction and progression free survival (PFS) and blood test results *etc.*

We gained the patients' informed consent for their participation. The Ethic Committee of Shanghai Ethical Committee of Human Genetic Resources approved this study. Patient recruiting, blood sample collection, clinical information collection and usage were performed according to the guideline and regulation of the committee.

Genotyping. We genotyped 48 SNP sites in EGFR, AKT1, CMET, CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP3A4, CYP3A5, UGT1A1, miRNA, ABCB1 and ABCG2. SNP selection were based on the literature review. We predicted the miRNA which possibly influenced the expression of EGFR based on the microRNA database miRBase³⁵. Germline genomic DNA was extracted from blood sample with Axygen Blood Genomic DNA Extraction Mini Kit. Genotyping was first performed with MassArray system (Sequenom, CA, USA). The genotyping was designed with Assay Design Suite 2.0 Software. 10–20 ng of genomic DNA was amplified with Gene Amp[®] PCR system 9700. The PCR product was then processed with iPLEX Gold assay and MassArray System (Sequenom, CA, USA). The SNP sites that were rejected by Assay Design Suite 2.0 were genotyped with ViiA[™]

7 System (life Technologies, Carlsbad, California) using TaqMan[®]. The genotyping probes were provided by the Applied Biosystems service. The PCR was performed with TaqMan Universal PCR Master Mix reagent kits in 5ul system (Foster City, California, USA) as the product guideline dictated.

Data analysis and statistics. The SNPs with success rate <90%, MAF <1% or homogeneous among all the samples were excluded in the following analyses. 40 SNPs were further analyzed (as shown in detail in supplementary file 1).

To reveal the genetic factors that were potentially responsible for different responses to target drugs to NSCLC, we used Response Evaluation Criteria in Solid Tumors (RECIST) system to evaluate the clinical response. We analyzed the association between the patients' genotypes and objective response to any of the drugs or specific drug (rated "partially response" versus "stable disease" and "progressive disease" in the first month of medication).

For ADRs we divided the patients in case and control group according to their clinical record on adverse drug reactions. The ADRs in our study were either skin injuries (mainly skin rash except one case of paronychia), digestive tract injuries (mainly diarrhea except one case of nausea and one case of nausea and diarrhea), or both.

The discrepancies of allele and genotype frequency of case and control, odds ratios (ORs) and their 95% confidence intervals (CIs), SNP case-control association analysis and Hardy-Weinberg equilibrium were calculated with SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>). Haplotype block construction was run by Haploview³⁶. The haplotype case-control association study was performed with SHEsis.

Multivariate interaction analyses were performed by multifactor dimensionality reduction (MDR) software³⁷. The threshold of statistical significance was p value <0.05 derived from 1000 permutations. The correlation between objective response to TKIs and ADR were calculated with SPSS (<http://www-01.ibm.com/software/analitics/spss/>).

References

- National Cancer Institute. *General Information About Non-Small Cell Lung Cancer (NSCLC)*, <http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/HealthProfessional/page1> (published in 2014) Date of access 09/05/2015.
- Bardelli, A. *et al.* Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers. *Science* **300**, 949, doi: 10.1126/science.1082596 (2003).
- Sawyers, C. L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. *Genes Dev* **17**, 2998–3010, doi: 10.1101/gad.1152403 (2003).
- Jorissen, R. N. *et al.* Epidermal growth factor receptor: mechanisms of activation and signalling. *Exp Cell Res* **284**, 31–53 (2003).
- Mayo, C. *et al.* Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. *Pharmacogenomics* **13**, 789–802, doi: 10.2217/pgs.12.54 (2012).
- Rosell, R. *et al.* Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *The Lancet Oncology* **13**, 239–246, doi: [http://dx.doi.org/10.1016/S1470-2045\(11\)70393-X](http://dx.doi.org/10.1016/S1470-2045(11)70393-X) (2012).
- Liu, S. & Kurzrock, R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. *Cancer Treatment Reviews* **40**, 883–891, doi: <http://dx.doi.org/10.1016/j.ctrv.2014.05.003> (2014).
- Zhou, C. *et al.* Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *The Lancet Oncology* **12**, 735–742, doi: [http://dx.doi.org/10.1016/S1470-2045\(11\)70184-X](http://dx.doi.org/10.1016/S1470-2045(11)70184-X) (2011).
- Riely, G. J. *et al.* Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. *Clinical Cancer Research* **12**, 839–844 (2006).
- Mitsudomi, T. & Yatabe, Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. *Cancer science* **98**, 1817–1824 (2007).
- Sequist, L. V., Bell, D. W., Lynch, T. J. & Haber, D. A. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology* **25**, 587–595 (2007).
- Liu, H. B. *et al.* Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. *PLoS One*. **8**, e55128. doi: 55110.51371/journal.pone.0055128. Epub 0052013 Jan 0055130 (2013).
- Petrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V. & Barni, S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. *Lung Cancer* **78**, 8–15, doi: <http://dx.doi.org/10.1016/j.lungcan.2012.06.009> (2012).
- Shah, D. R., Shah, R. R. & Morganroth, J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. *Drug Saf* **36**, 413–426, doi: 10.1007/s40264-013-0050-x (2013).
- Xu, Y., Tan, L. J., Grachtchouk, V., Voorhees, J. J. & Fisher, G. J. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. *J Biol Chem*. **280**, 42694–42700. Epub 42005 Oct 42631 (2005).
- Mattila, E. *et al.* Negative regulation of EGFR signalling through integrin- α 1 β 1-mediated activation of protein tyrosine phosphatase TCPTP. *Nat Cell Biol*. **7**, 78–85. Epub 2004 Dec 2012 (2005).
- Liu, W. *et al.* A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. *Cancer Res* **65**, 46–53 (2005).
- Brandt, B. *et al.* Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. *Cancer Res* **64**, 7–12 (2004).
- Liu, G. *et al.* Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. *Pharmacogenomics J* **8**, 129–138, doi: 10.1038/sj.tpj.6500444 (2008).
- Rudin, C. M. *et al.* Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity. *Journal of Clinical Oncology* **26**, 1119–1127, doi: 10.1200/jco.2007.13.1128 (2008).
- Bardelli, A. *et al.* Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer discovery* **3**, 658–673, doi: 10.1158/2159-8290.cd-12-0558 (2013).
- Ryan, B. M., Robles, A. I. & Harris, C. C. Genetic variation in microRNA networks: the implications for cancer research. *Nat Rev Cancer*. **10**, 389–402. doi: 310.1038/nrc2867. (2010).
- Whirl-Carrillo, M. *et al.* Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther* **92**, 414–417, doi: 10.1038/clpt.2012.96 (2012).
- Ruan, C. J., Liu, D. Y., Jiang, J. & Hu, P. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. *Eur J Clin Pharmacol* **68**, 1677–1680, doi: 10.1007/s00228-012-1288-4 (2012).
- Lemos, C. *et al.* Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. *Pharmacogenomics*. **12**, 159–170. doi: 110.2217/pgs.2210.2172 (2011).

26. Cusatis, G. *et al.* Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. *J Natl Cancer Inst.* **98**, 1739–1742 (2006).
27. Suzumura, T. *et al.* Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. *BMC Cancer* **12**, 568, doi: 10.1186/1471-2407-12-568 (2012).
28. Kobayashi, H. *et al.* Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. *Clin Lung Cancer*, doi: 10.1016/j.clcc.2014.12.004 (2014).
29. Chu, H. *et al.* EGFR 3' UTR 774T > C polymorphism contributes to bladder cancer risk. *Mutagenesis* **28**, 49–55, doi: 10.1093/mutage/ges051 (2013).
30. Lee, S. T. *et al.* Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. *J Clin Psychopharmacol.* **32**, 441–448. doi: 10.1097/JCP.1090b1013e31825ac31835c (2012).
31. Xu, M. Q. *et al.* Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. *J Clin Psychiatry.* **68**, 1358–1367 (2007).
32. Ikeda, M. *et al.* Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. *Pharmacogenomics.* **9**, 1437–1443. doi: 1410.2217/14622416.14622419.14622410.14621437 (2008).
33. Wang, Y. *et al.* Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population. *J Oral Pathol Med.* **44**, 45–50. doi: 10.1111/jop.12211. Epub 12014 Jul 12224 (2015).
34. Kim, M. J. *et al.* AKT1 polymorphisms and survival of early stage non-small cell lung cancer. *J Surg Oncol.* **105**, 167–174. doi: 110.1002/jso.22071. Epub 22011 Aug 22012 (2012).
35. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res.* **42**, D68–73. doi: 10.1093/nar/gkt1181. Epub 2013 Nov 1025 (2014).
36. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* **21**, 263–265 (2005).
37. Hahn, L. W., Ritchie, M. D. & Moore, J. H. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. *Bioinformatics.* **19**, 376–382 (2003).

Acknowledgements

We sincerely thank all the patients who agreed to participate in the study and all the staff who helped with sample collection and lab work. We also sincerely thank our colleagues in King's College London for their great help and inspiration during the manuscript preparation. This work was supported by grants from the 863 Program (2012AA02A515, 2012AA021802), the 973 Program (2010CB529600), the National Key Technology R&D Program (2012BAI01B09), the National Nature Science Foundation of China (81121001, 81273596, J1210047, 30900799, 30972823), Shanghai Municipal Commission of Science and Technology Program (11DZ1950300, 09DJ1400601), the Public Health Key Disciplines in Shanghai-Health Microbiology (12GWZX0801), Public Science and Technology Research Funds (201210056), the Shanghai Jiao Tong University Interdisciplinary Research fund, and the Shanghai Leading Academic Discipline Project (B205).

Author Contributions

Conception and design: S.Q. Sample process: X.Z., J.J., Y.R., M.L., H.D. and C.M. Analysis: Y.R., J.J., M.L., L.H. and H.D. Interpretation of data: Y.R., J.J., L.G., S.L., H.H. and Y.L. Drafting the article: Y.R., J.J. and S.Q. Critical revision: all authors. Final approval: all authors.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Ruan, Y. *et al.* Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients. *Sci. Rep.* **6**, 23368; doi: 10.1038/srep23368 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>